Heteroleptic arene Ru(ii) dipyrrinato complexes: DNA, protein binding and anti-cancer activity against the ACHN cancer cell line?

Dalton Transactions Pub Date: 2016-03-09 DOI: 10.1039/C6DT00446F

Abstract

Four organometallic complexes [(η6-C6H6)RuCl(pmpzdpm)], 1; [(η6-C6H6)RuCl(pypzdpm)], 2; [(η6-C10H14)RuCl(pmpzdpm)], 3 and [(η6-C10H14)RuCl(pypzdpm)], 4 containing 5-(2-pyrimidyl-piperazine)phenyldipyrromethene (pmpzdpm) and 5-(2-pyridylpiperazine)phenyldipyrromethene (pypzdpm) have been designed and synthesized. The complexes 1–4 have been fully characterized by elemental analyses and spectroscopic studies (ESI-MS, IR, 1H, 13C NMR, UV–vis). Their electrostatic/intercalative interaction with CT DNA has been investigated by UV–vis and competitive ethidium bromide displacement studies while their protein binding affinity toward bovine serum albumin (BSA) was realized by UV–vis, fluorescence, synchronous and three dimensional (3D) fluorescence studies. The interaction with DNA and protein has further been validated by in silico studies. Cellular uptake, in vitro cytotoxicity and flow cytometric analyses have been performed to determine the mode of cell death against the kidney cancer cell line ACHN. Cell cycle analysis suggested that the complexes cause cell cycle arrest in the subG1 phase and overall results indicated that the in vitro antitumor activity of 1–4 lies in the order of 3 > 4 > 1 > 2 (IC50, 7.0 1; 8.0 2; 2.0 3; 4.0 μM, 4).

Graphical abstract: Heteroleptic arene Ru(ii) dipyrrinato complexes: DNA, protein binding and anti-cancer activity against the ACHN cancer cell line
Recommended Literature